


# Blood Eosinophils and COPD


Despite advances in the management of COPD, tailoring therapy to individual patients is still a key challenge




This blood marker might help physicians decide on an individual patient basis who may/may not benefit from the addition of ICS to LAMA/LABA to reduce their risk of COPD exacerbations<sup>1-5</sup>

Blood eosinophils may also assist in the decision of ICS discontinuation in selected patients<sup>3,4</sup>

## Blood eosinophils may help tailor therapy to individual patients with COPD



## What is the right “cut-off-value”?



References: 1. Watz H, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. *Lancet Respir Med.* May 2016. 2. Bushnell N, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment: data from the FLAME trial. *Am J Respir Crit Care Med.* May 2017. 3. Harlander M, et al. Should Patients Switched from the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids? COPD: Int J Chron Obstruct Pulmon Dis. 2017. 4. Tariq S M, et al. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/ICS? Int J Chron Obstruct Pulmon Dis. 2017. 5. Calverley P. Light in the Darkness? The FLAME Trial, Blood Eosinophils, and Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med.* May 2017. 6. Medscape: Pulmonary Disease Workup. Available at: <http://emedicine.medscape.com/article/301070-workup>. Last accessed: December 2017. 7. Calverley P, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* March 2017

